Infliximab in inflammatory bowel disease

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD. Data from randomized controlled trials, large obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Papamichael, Konstantinos, Lin, Steve, Moore, Matthew, Papaioannou, Garyfallia, Sattler, Lindsey, Cheifetz, Adam S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435871/
https://www.ncbi.nlm.nih.gov/pubmed/30937157
http://dx.doi.org/10.1177/2040622319838443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435871/
https://www.ncbi.nlm.nih.gov/pubmed/30937157
http://dx.doi.org/10.1177/2040622319838443

Ejemplares similares